These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 28448177

  • 1. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Stoimenis D, Karagiannis T, Katsoula A, Athanasiadou E, Kazakos K, Bekiari E, Matthews DR, Tsapas A.
    Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
    [Abstract] [Full Text] [Related]

  • 2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X, Divino V, Amamoo J, Xie L, Coyle KB, Gamble CL, Guevarra M, Paprocki Y, King AA.
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Kamrul-Hasan ABM, Alam MS, Talukder SK, Dutta D, Selim S.
    Endocrinol Metab (Seoul); 2024 Feb; 39(1):109-126. PubMed ID: 38417828
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z, Sun J, Han R, Fan D, Dong X, Luan Z, Xiang R, Zhao M, Yang J.
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [Abstract] [Full Text] [Related]

  • 6. Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.
    Yang W, Cai X, Gao X, Chen Y, Chen L, Ji L.
    J Diabetes Investig; 2018 Jul; 9(4):813-821. PubMed ID: 29047219
    [Abstract] [Full Text] [Related]

  • 7. Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus.
    Zhao L, Meng J, Bai X, Zhang D, Yang X, Yang Y, Cai G, Liu X.
    Eur J Med Res; 2024 Jul 12; 29(1):363. PubMed ID: 38997754
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.
    Chai S, Niu Y, Liu F, Wu S, Yang Z, Sun F.
    J Diabetes Res; 2024 Jul 12; 2024():8145388. PubMed ID: 39072050
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
    Wang X, Li X, Qie S, Zheng Y, Liu Y, Liu G.
    Medicine (Baltimore); 2018 Aug 12; 97(34):e11946. PubMed ID: 30142816
    [Abstract] [Full Text] [Related]

  • 14. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis.
    Tricco AC, Antony J, Khan PA, Ghassemi M, Hamid JS, Ashoor H, Blondal E, Soobiah C, Yu CH, Hutton B, Hemmelgarn BR, Moher D, Majumdar SR, Straus SE.
    BMJ Open; 2014 Dec 23; 4(12):e005752. PubMed ID: 25537781
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study.
    Inagaki N, Sano H, Seki Y, Kuroda S, Kaku K.
    J Diabetes Investig; 2018 Mar 23; 9(2):354-359. PubMed ID: 28836351
    [Abstract] [Full Text] [Related]

  • 18. Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies on dietary sodium intake.
    Okada S, Okada K, Okada J, Kikkawa K, Yamada E, Saito T, Andou T, Ohshima K.
    Diabetes Metab Syndr; 2023 Jul 23; 17(7):102806. PubMed ID: 37343509
    [Abstract] [Full Text] [Related]

  • 19. Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study.
    Zareini B, Sørensen KK, Pedersen-Bjergaard U, Loldrup Fosbøl E, Køber L, Torp-Pedersen C.
    J Diabetes; 2024 Jun 23; 16(6):e13560. PubMed ID: 38751369
    [Abstract] [Full Text] [Related]

  • 20. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
    Longo M, Caruso P, Scappaticcio L, Maiorino MI, Bellastella G, Capuano A, Esposito K, Giugliano D.
    Diabetes Obes Metab; 2024 Apr 23; 26(4):1492-1501. PubMed ID: 38234208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.